Immunohistochemistry as an adjunct in the differential diagnosis of radiation-induced atypia versus urothelial carcinoma in situ of the bladder: a study of 45 cases

Epstein, 1998, The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee, Am J Surg Pathol, 22, 1435, 10.1097/00000478-199812000-00001 Nese, 2009, Carcinoma in situ of the urinary bladder: review of clinicopathologic characteristics with an emphasis on aspects related to molecular diagnostic techniques and prognosis, J Natl Compr Canc Netw, 7, 48, 10.6004/jnccn.2009.0004 Cheng, 1999, Survival of patients with carcinoma in situ of the urinary bladder, Cancer, 85, 2469, 10.1002/(SICI)1097-0142(19990601)85:11<2469::AID-CNCR24>3.0.CO;2-U Shariat, 2007, Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ-confined TCC at radical cystectomy, Eur Urol, 51, 152, 10.1016/j.eururo.2006.08.037 Kaufman, 1993, Selective bladder preservation by combination treatment of invasive bladder cancer, N Engl J Med, 329, 1377, 10.1056/NEJM199311043291903 Shipley, 2002, Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer, Urology, 60, 62, 10.1016/S0090-4295(02)01650-3 Weiss, 2008, Management of superficial recurrences in an irradiated bladder after combined-modality organ-preserving therapy, Int J Radiat Oncol Biol Phys, 70, 1502, 10.1016/j.ijrobp.2007.08.007 Zietman, 2001, Selective bladder conservation using transurethral resection, chemotherapy, and radiation: management and consequences of Ta, T1, and Tis recurrence within the retained bladder, Urology, 58, 380, 10.1016/S0090-4295(01)01219-5 Baker, 2000, Radiation-induced pseudocarcinomatous proliferations of the urinary bladder: a report of 4 cases, Hum Pathol, 31, 678, 10.1053/hupa.2000.7894 Chan, 2004, Radiation or chemotherapy cystitis with “pseudocarcinomatous” features, Am J Surg Pathol, 28, 909, 10.1097/00000478-200407000-00010 Lopez-Beltran, 2002, Changes produced in the urothelium by traditional and newer therapeutic procedures for bladder cancer, J Clin Pathol, 55, 641, 10.1136/jcp.55.9.641 McKenney, 2001, Discriminatory immunohistochemical staining of urothelial carcinoma in situ and non-neoplastic urothelium: an analysis of cytokeratin 20, p53, and CD44 antigens, Am J Surg Pathol, 25, 1074, 10.1097/00000478-200108000-00013 Moll, 1992, Cytokeratin 20 in human carcinomas. A new histodiagnostic marker detected by monoclonal antibodies, Am J Pathol, 140, 427 Mallofre, 2003, Immunohistochemical expression of CK20, p53, and Ki-67 as objective markers of urothelial dysplasia, Mod Pathol, 16, 187, 10.1097/01.MP.0000056628.38714.5D Sarkis, 1994, Association of P53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder, J Urol, 152, 388, 10.1016/S0022-5347(17)32745-3 Shariat, 2003, Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder, Urology, 61, 1140, 10.1016/S0090-4295(03)00236-X Tashiro, 1997, p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis, Am J Pathol, 150, 177 Hodges, 2010, Urothelial dysplasia and other flat lesions of the urinary bladder: clinicopathologic and molecular features, Hum Pathol, 41, 155, 10.1016/j.humpath.2009.07.002 Yin, 2008, p16ink4 immunoreactivity is a reliable marker for urothelial carcinoma in situ, Hum Pathol, 39, 527, 10.1016/j.humpath.2007.08.005 Sun, 2002, p53 protein and Ki-67 overexpression in urothelial dysplasia of bladder, Appl Immunohistochem Mol Morphol, 10, 327, 10.1097/00129039-200212000-00007 Yin, 2006, Cytokeratin 20 and Ki-67 to distinguish carcinoma in situ from flat non-neoplastic urothelium, Appl Immunohistochem Mol Morphol, 14, 260, 10.1097/00129039-200609000-00002 Desai, 2000, Relationship of cytokeratin 20 and CD44 protein expression with WHO/ISUP grade in pTa and pT1 papillary urothelial neoplasia, Mod Pathol, 13, 1315, 10.1038/modpathol.3880241 Harnden, 1999, Expression of cytokeratin 20 redefines urothelial papillomas of the bladder, Lancet, 353, 974, 10.1016/S0140-6736(98)05383-5 Alsheikh, 2001, Comparison of the WHO/ISUP classification and cytokeratin 20 expression in predicting the behavior of low-grade papillary urothelial tumors. World/Health Organization/Internattional Society of Urologic Pathology, Mod Pathol, 14, 267, 10.1038/modpathol.3880300 Yildiz, 2009, Utility of a dual immunostain cocktail comprising of p53 and CK20 to aid in the diagnosis of non-neoplastic and neoplastic bladder biopsies, Diagn Pathol, 4, 35, 10.1186/1746-1596-4-35 Lohmann, 1993, Accumulation of p53 protein as an indicator for p53 gene mutation in breast cancer. Occurrence of false-positives and false-negatives, Diagn Mol Pathol, 2, 36, 10.1097/00019606-199303000-00006 Gallucci, 2005, Status of the p53, p16, RB1, and HER-2 genes and chromosomes 3, 7, 9, and 17 in advanced bladder cancer: correlation with adjacent mucosa and pathological parameters, J Clin Pathol, 58, 367, 10.1136/jcp.2004.021154 Screaton, 1993, The identification of a new alternative exon with highly restricted tissue expression in transcripts encoding the mouse Pgp-1 (CD44) homing receptor. Comparison of all 10 variable exons between mouse, human, and rat, J Biol Chem, 268, 12235, 10.1016/S0021-9258(18)31376-0 Goodison, 1999, CD44 cell adhesion molecules, Mol Pathol, 52, 189, 10.1136/mp.52.4.189 Kuncova, 2007, Expression of CD44s and CD44v6 in transitional cell carcinomas of the urinary bladder: comparison with tumour grade, proliferative activity and p53 immunoreactivity of tumour cells, APMIS, 115, 1194, 10.1111/j.1600-0643.2007.00602.x Ross, 1996, Expression of the CD44 cell adhesion molecule in urinary bladder transitional cell carcinoma, Mod Pathol, 9, 854 Stavropoulos, 2001, CD44 standard form expression as a predictor of progression in high risk superficial bladder tumors, Int Urol Nephrol, 33, 479, 10.1023/A:1019589923706 Toma, 1999, Focal loss of CD44 variant protein expression is related to recurrence in superficial bladder carcinoma, Am J Pathol, 155, 1427, 10.1016/S0002-9440(10)65455-7 Woodman, 2000, Noninvasive diagnosis of bladder carcinoma by enzyme-linked immunosorbent assay detection of CD44 isoforms in exfoliated urothelia, Clin Cancer Res, 6, 2381 Russo, 2007, A useful panel in proliferative urothelial lesions: an analysis of cytokeratin 20, p53, CD44 and Ki-67 antigens, Pathologica, 99, 46